LNF1901 not checked

Shandong New Time Pharmaceutical Co., LTD

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“LNF1901,7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg,IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.”In the company’s words, NCT06226363 on ClinicalTrials.gov
Tested for
Advanced Malignant Tumors
Main trialPhase 1
“This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.”In the company’s words, NCT06226363 on ClinicalTrials.gov

Other drugs for Advanced Malignant Tumors

All 392 drugs for Advanced Malignant Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 1 Feb 2025 Phase I Study of LNF1901 in Advanced Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LNF1901

Following is part of Solo: you see every change to LNF1901 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in